p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: Possible biopotential markers in human prostatic cancer

Urology

Volumn 48, Issue 2, 1996, Pages 261-268

  Papadopoulos, Ilias ^a,b   Rudolph, Pierre ^a   Wirth, Bruno ^a   Weichert Jacobsen, Klaus ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURGERY; DNA CONTENT; DNA DETERMINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION;

EID: 0030218872     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00169-0     Document Type: Article

References (51)

1. 1. Ackermann R: Prognostische Faktoren beim Prostatakarzinom, in Altwein JE, Bartsch G, Hohenfellner R, Huland H, Rübben H, and Weissbach L (Eds): Therapie urologischer Tumoren. München, Karger, 1990, pp 63-65.
2. 2. Hammerer P, and Huland H: Zur Diagnostik des lokalisierten Prostatakarzinoms: screening und präoperatives staging [Diagnosis of localized prostate cancer: screening and preoperative staging]. Urologe [A] 30: 378-386, 1991.
3. 3. Partin AW, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 20: 713-725, 1993.
4. 4. Barnes R, Hirst A, and Rosenquist R: Early carcinoma of the prostate: comparison of stages A and B. J Urol 115: 404-411, 1976.
5. 5. Brandes D: Prostate carcinoma, in Hill GS (Ed): Uropathology. New York, Churchill Livingstone, 1989, pp 1203-1258.
6. 6. Kramer SA, Farnham R, Glenn JF, and Paulson DF: Experience with Gleason histopathologic grading in prostatic cancer. J Urol 124: 223-232, 1980.
7. 7. Jenkins JR, and Sturzbecher HW: The p53 oncogene, in Reddy EP (Ed): The Oncogene Handbook. Amsterdam, Elsevier, pp 403-423.
8. 8. van den Berg FM, Tigges AJ, Schipper MEI, den Hartog-Jager FC, Kroes WG, and Walboomers JM: Expression of the nuclear oncogene p53 in colon tumours. J Pathol 157: 193-199, 1989.
9. 9. Cattoretti G, Rilke F, Andreola S, D'Amato L, and Delia D: p53 expression in breast cancer. Int J Cancer 41: 178-183, 1988.
10. 10. Iggo R, Gatter K, Bartek J, Lane D, and Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-679, 1990.
11. 11. Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Home CH, and Neal DE; Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer 63: 967-970, 1991.
12. 12. Hollstein M, Sidransky D, Vogelstein B, and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
13. 13. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, and Iglehart JD: Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 219: 332-341, 1994.
14. 14. Kreipe H, Wacker HH, Heidebrecht HJ, Haas K, Hauberg M, Tiemann M, and Parwaresch R: Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol 142: 1689-1694, 1993.
15. 15. Rudolph P, Lappe T, Schubert C, Schmidt D, Parwaresch RM, and Christophers E: Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Am J Pathol 147: 1615-1625, 1995.
16. 16. Gerdes J, Li L, Schlüter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, and Flad HD: Immunobiochemical and molecular biologic characterization of the cell proliferation associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867-873, 1991.
17. 17. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
18. 18. Schwarting R: Little missed markers and Ki-67. Lab Invest 68: 597-599, 1993.
19. 19. Rudolph P, Lappe T, Hero B, Berthold F, Parwaresch R, Harms D, and Schmidt D: Prognostic significance of the proliferative activity in neuroblastoma. J Clin Oncol (in press).
20. 20. Papadopoulos I, Rudolph P, Weichert-Jacobsen K, and Thiemann O: Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine. Urology 48: 1996 (in press).
21. 21. Winkler HZ, Rainwater LM, Myers RP, Farrow GM, Therneau TM, Zincke H, and Lieber MM: Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin Proc 63: 103-112, 1988.
22. 22. Yokogi H, Mizutani M, and Ishibe T: Flow cytometric DNA analysis of stage D2 prostatic carcinoma. Urol Int 47: 57-59, 1991.
23. 23. Gleason DF: Classification of prostate carcinomas (part 1). Cancer Chemother Rep 50: 125, 1966.
24. 24. Hermanek P, and Sobin LH: TNM Classification, 4th ed., 2nd rev. Berlin: Springer, 1992, pp 141-144.
25. 25. Shi SR, Key ME, and Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave overheating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
26. 26. Reith A, and Danielsen H: Assessment of DNA ploidy in tumor material, in Wied GL, Bartels PH, Rosenthal DL, and Schenk V (Eds): Compendium on the Computerized Cytology and Histology Laboratory. Chicago, Tutorials of Cytology, 1994, pp 185-193.
27. 27. Jenkins JR, and Sturzbecher HW: The p53 oncogene, in Reddy EP (Ed): The Oncogene Handbook. Amsterdam, Elsevier, 1988, pp 403-423.
28. 28. Perry ME, and Levine AJ: Tumor-suppressor p53 and the cell cycle. Curr Opin Genet Dev 3: 50-54, 1993.
29. 29. Soini Y, Pääkkö P, Nuorva K, Kamel D, Lane DP, and Vähäkangas K: Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Archiv [A] 421: 223, 1992.
30. 30. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, and Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883-887, 1992.
31. 31. Van Veldhuizen PJ, Sadasivan R, Garcia F, Austenfeld MS, and Stephens RL: Mutant p53 expression in prostate carcinoma. Prostate 22: 23-30, 1993.
32. 32. Dowell SP, Lane DP, and Hall PA: The immunocytochemical detection of p53 protein in cytological specimens: technical considerations. Cytopathology 5: 76-81, 1994.
33. 33. Bookstein R, McGrogan D, Hilsenbeck SG, Sharkey F, and Alfred DC: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369-3373, 1993.
34. 34. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, and Srivastava S: Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 154: 414-421, 1995.
35. 35. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
36. 36. Oren M: Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 5: 221-227, 1994.
37. 37. Gallee MPW, Visser-deJong E, ten Kate FJW, Schroeder FH, and Van der Kwast TH: Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. J Urol 142: 1342-1346, 1989.
38. 38. Raymond WA, Leong ASY, Bolt JW, Milios J, and Jose JS: Growth fractions in human prostatic carcinoma determined by Ki-67 immunostaining. J Pathol 156: 161-167, 1988.
39. 39. Rudolph P, Lappe TH, Kreipe H, Parwaresch MR, and Schmidt D: Assessment of the growth fraction in prostate cancer by means of the nuclear proliferation associated formalin-resistant antigen Ki-S5. Verh Dtsch Ges Pathol 77: 98, 1993.
40. 40. Böcking A, Kiehn J, and Heinzel-Wach M: Combined histologic grading of prostatic carcinoma. Cancer 50: 288, 1982.
41. 41. Stamey TA: Prostate-specific antigen: its role in diagnosis and treatment of prostate adenocarcinoma. Urologe [A] 29: 52, 1990.
42. 42. Jurincic CD, Pixberg HU, Gasser A, and Klippel KF: Prostate-specific antigen in prostatic carcinoma. Urol Int 45: 153, 1990.
43. 43. Boecking A: Prognostic relevance of cytometric methods for tumors of the urinary tract and prostate. Verh Dtsch Ges Pathol 77: 161, 1993.
44. 44. Falkmer UG: Methodologic sources of errors in image and flow cytometric DNA assessments of the malignancy potential of prostatic carcinoma. Hum Pathol 23: 360, 1992.
45. 45. Ellis WJ, and Brawer MK: PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia. Urol Clin North Am 20: 621, 1993.
46. 46. Radinsky R, Fidler IJ, Price JE, Esumi N, Tsan R, Petty CM, Bucana CD, and Bar Eli M: Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene 9: 1877, 1994.
47. 47. Ryan JJ, and Clarke MF: Alteration of p53 conformation and induction of apoptosis in a murine erythroleukemia cell line by dimethylsulfoxide. Leuk Res 18: 617, 1994.
48. 48. Zhu YM, Bradbury DA, and Russell NH: Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer 69: 468-472, 1994.
49. 49. Merrit AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, and Hall PA: The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54: 614, 1994.
50. 50. Lowe SW, Schmitt EM, Smith SW, Osborne BA, and Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847, 1993.
51. 51. Berges RR, Furuya Y, Remington L, English HF, Jacks T, and Isaacs JT: Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA 90: 8910-8914, 1993.